FCMV
CRVS icon

Foresite Capital Management VI’s Corvus Pharmaceuticals CRVS Stock Holding History

Foresite Capital Management VI’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26.8M Buy
1,831,233
+450,000
+33% +$7.18M 5.82% 4
2025
Q4 		$10.6M Sell
1,381,233
-350,000
-20% -$2.76M 3.21% 11
2025
Q3 		$12.8M Hold
1,731,233
– – 4.93% 7
2025
Q2 		$6.92M Buy
1,731,233
+150,000
+9% +$546K 3.89% 9
2025
Q1 		$5.03M Hold
1,581,233
– – 2.75% 10
2024
Q4 		$8.46M Buy
+1,581,233
New +$11.8M 3.77% 9

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Foresite Capital Management VI's CRVS Position: Q1 2026 in Review

Foresite Capital Management VI increased its Corvus Pharmaceuticals (CRVS) stake by 33% in Q1 2026, buying an estimated $7.18M and bringing the position to 1,831,233 shares worth $26.8M. The position accounts for 5.82% of the portfolio, ranked #4.

Foresite Capital Management VI first reported a position in CRVS in Q4 2024 and has held it in 6 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Foresite Capital Management VI held 1,831,233 shares of Corvus Pharmaceuticals worth $26.8M as of Q1 2026.
  • Foresite Capital Management VI bought 450,000 Corvus Pharmaceuticals shares in Q1 2026, an estimated $7.18M.
  • Corvus Pharmaceuticals made up 5.82% of Foresite Capital Management VI's portfolio in Q1 2026, its #4 holding.
  • Foresite Capital Management VI first reported a position in Corvus Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Foresite Capital Management VI's 13F filing for Q1 2026, filed 15 May 2026.